Dr. Lupo Antonella
Orthoptist / Assistant in Ophthalmology
Linea di ricerca: Glaucoma and anterior segment with ocular annexes
Unità di ricerca: UR Glaucoma
Unità Operativa Semplice: UOS Glaucoma and Local Hospital Integration
06/19/2021. 1st level Master in “New techniques and strategies of visual rehabilitation”. University of Rome “La Sapienza”
20/05/2019. Advanced course in low vision and visual rehabilitation for adults: “Qualified expert in low vision”. International School of Optics and Optometry (S.I.O.O)
19/03/2016. 1st level Master in “Assistance in ophthalmic surgery”University of Rome – “La Sapienza”
14/11/2014. 1st level degree in “Orthoptics and assistance in ophthalmology”. University of Rome “TorVergata” Faculty of Medicine and Surgery.
- 2022 to date Permanent employee as Orthoptist and assistant in ophthalmology at IRCCS G.B. Bietti
- 2016/2021 Contractor as orthoptist and assistant in ophthalmology at IRCCS G.B. Bietti
2022 to date Permanent employee as Orthoptist and assistant in ophthalmology at IRCCS G.B. Bietti
Sub-Investigator of the following clinical trials:
- Modulazione della connettività neuronale lungo le vie ottiche nei pazienti glaucomatosi tramite trattamento con citicolina in soluzione orale: studio morfo-funzionale multimodale
- Efficacy and safety assessment of T4030 eye drops versusGanfort® UD in ocular hypertensive or glaucomatous patients. LT4030-301
- A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension TRITON 1698-301-007
- Basic human research studyof novel glaucoma endpoints and identification of optimal patient populations forneuroprotection trials CBASICHR0031
- Valutazione della spatial summation nei 10 gradi centrali del campo visivo: sviluppo di un modello neurale per analisi struttura – funzione
- Efficacia nelle 24 ore e tollerabilità dell’associazione fissa tafluprost –timololo senza conservanti nei pazienti glaucomatosi o ipertesi oculari già in trattamento con latanoprost conservato con BAK. Studio prospettico in aperto della durata di 3 mesi. HERO
- Valutazione dell’agreement nella diagnosi di progressione campimetrica del glaucoma